News
Three Motley Fool contributors have picked surprisingly underrated stocks to buy right now. Here's why they chose big pharma ...
Analysts estimate that Merck & Co will report an earnings per share (EPS) of $2.01. Investors in Merck & Co are eagerly ...
Merck has had a successful track record of beating estimates, having surpassed EPS expectations 88% of the time and beating ...
Merck & Co., Inc. (NYSE:MRK) is one of the top low volatility healthcare stocks to buy now. Analyst Daina Graybosch of ...
The deal, which will focus first on a COPD therapy GSK believes holds “best-in-class” potential, could ultimately involve a ...
Shares of GSK fell to below $30 around the time of the demerger, but have since recovered to about $36. The 20% gain over 34 ...
Explore more
Merck & Co., Inc. (NYSE:MRK) is included among the 11 Dogs of the Dow Dividend Stocks to Buy Now. Merck & Co., Inc. (NYSE:MRK ...
Signals suggest the drugs could improve on the standard of care, but the market may not make it easy for another megablockbuster to rise to the top.
Poster presentation of updated data on BT-001 from the Phase 1 part of the ongoing Phase 1/2a study in solid tumors - LUND, SE / ACCESS Newswire / July 28, 2025 / BioInvent International AB ("BioInven ...
For a business, there are advantages to taking a political stand—but there’s a fine line between brand enhancement and ...
Global pharmaceutical giants make billions of dollars in Australia but pay a fraction of that in tax. They say the price they ...
The latest announcement comes from Simtra BioPharma Solutions, a global CDMO, with US headquarters located in Parsippany, NJ.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results